Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer

MRI and PSMA-PET are highly sensitive imaging tools for prostate cancer, yet they often detect different lesions. These discordant findings pose clinical uncertainty because their biological significance is unclear. This project aims to molecularly characterize MRI-PSMA PET discordant lesions using high-quality biobanked samples from patients enrolled in an institutional study (NCT06187870). By integrating imaging and molecular data, the study will clarify whether these lesions represent indolent disease, aggressive subclones, or biologically distinct entities, and will assess their clinical implications.

NCT Number	NCT07485257
Lead Sponsor	IRCCS San Raffaele
Conditions	Prostate Cancer, Molecular Imaging, Transcriptomics, RNA, PSMA PET/CT
Enrollment	30 participants
Start Date	2023-12-04
Primary Completion	2025-12-09 (estimated)
Study Completion	2025-12-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-15